Affordable Access

deepdyve-link
Publisher Website

The presence of SARS-CoV2 antibodies in MS patients

Authors
  • Wallach, Asya I.
  • Picone, Mary Ann
Type
Published Article
Journal
Multiple Sclerosis and Related Disorders
Publisher
Elsevier B.V.
Publication Date
Jan 23, 2021
Volume
50
Pages
102793–102793
Identifiers
DOI: 10.1016/j.msard.2021.102793
PMID: 33588315
PMCID: PMC7825833
Source
PubMed Central
Keywords
License
Unknown

Abstract

Background The COVID-19 pandemic has raised novel concerns for people living with MS regarding their safety. Methods Observational study of patients at a single comprehensive community MS center. Results 48 patients with MS were suspected of developing COVID-19 March to May 2020; 2 died. Of the remainder, 17 were tested for COVID-19 antibodies as part of routine care. Average age of this subgroup was 49.8y ± 11.3 (age range 32-67), 76% female. 65% were treated with an anti-CD20 drug, 12% untreated, and 6% each received glatiramer acetate, interferon, natalizumab, or teriflunomide. 59% of patients were antibody negative. Conclusions The low incidence of SARS CoV2 antibodies following infection suggests that certain DMTs may alter SARS CoV2-Ab response or persistence.

Report this publication

Statistics

Seen <100 times